NCI-H187細(xì)胞

器官來源： 肺

細(xì)胞形態(tài)： 上皮樣

ATCC Number： CRL-5804?

相關(guān)**： 小細(xì)胞肺癌

是否是腫瘤細(xì)胞： 1

物種來源： 人

生長狀態(tài)： 懸浮生長，多細(xì)胞聚集

運輸方式： 凍存運輸

年限： 47 years

數(shù)量： 大量

Designations: NCI-H187 [H187]

Depositors: AF Gazdar, JD Minna

NCI-H187細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension, multicell aggregates

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: carcinoma; classic small cell lung cancer

Derived from metastatic site: pleural effusion

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: NCI-H187細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Tumorigenic: Yes

Oncogene: c-kit +; N-myc +

DNA Profile (STR): Amelogenin: X

CSF1PO: 11

D13S317: 12

D16S539: 11

D5S818: 12

D7S820: 9,10

THO1: 9.3

TPOX: 8

vWA: 16,17

Age: 47 years

Gender: male

Ethnicity: Caucasian

Comments: NCI-H187細(xì)胞This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from cells recovered from pleural effusion obtained from a patient prior to therapy.

NCI-H187 expresses elevated levels of the 4 biochemical markers of SCLC: neuron-specific enolase, the brain isoenzyme of creatine kinase, L-dopa carboxylase and bombesin-like immunoreactivity.

Only trace amounts of the retinoblastoma susceptibility gene (RB) mRNA, were detected.

RB protein was not detected.

The cells express the c-kit gene as well as the N-myc gene.

N-myc is not amplified.

The cells are not able to synthesize the peptide neuromedin B (NMB) or the gastrin-releasing peptide (GRP).

They express easily detectable levels of p53 mRNA compared to levels found in normal lung.

These cells are useful for transfection studies.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%

Storage temperature: NCI-H187細(xì)胞liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

23106: Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933

23320: Kaye FJ, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926, 1990. PubMed: 2168563

23517: Giaccone G, et al. Neuromedin B is present in lung cancer cell lines. Cancer Res. 52: 2732s-2736s, 1992. PubMed: 1563005

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.